In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.

March 9, 2007 -- A new analysis that compared 3 common treatment options for prostate cancer found a difference between them. Men who were treated with external-beam radiotherapy did not live as long ...

SBRT reduced biochemical failure and acute GU toxicity compared with HDR brachytherapy in intermediate-risk prostate cancer.

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

Long-used imaging strategies such as computed tomography (CT) and bone scintigraphy (BS) to detect lymph node and bone metastases have significant limitations and disadvantages. Newly emerging ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

For the last three years, Bayer has been implementing a new strategy for its oncology development, a strategy that led to ...

Performed in a single session without any surgical incisions or scarring, the treatment utilizes an advanced fusion-guided ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting ...